BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue missed and the company lowered FY25 organic growth guidance. The quarter likely adds to investor worries on the plasma market recovery and durability of Vascade growth, notes the analyst, who also expects tariffs to remain “somewhat of an overhang” as Haemonetics has higher exposure to Mexico and Canada.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue